Testicular tumors.

Slides:



Advertisements
Similar presentations
Testicular tumors Mostafa El- Haddad.
Advertisements

UNDERWRITING CORRELATION FOR CANCER CASES. Are we going to accept a proposed insured with known cancer?
Management of Testicular Tumours
CRYPTORCHIDISM Dr.GOVIND SRMC & RI.
TUMORS OF THE TESTIS GERM CELL TUMORS.
Tumors of the testis S. Vahidi M.D.
PARATESTICULAR TUMORS
Pimp Session: Breast By James Lee, MD.
TNM staging and prognosis Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania.
Testicular Tumours Part 2
Epidemiology Are rare, lifetime probability 0.2%
Organ-Preserving Surgery for Testicular Neoplasms
TUMORI DEL TESTICOLO.
Testis Dr. Raid Jastania.
Management of Testicular Cancer
UBC Department of Urologic Sciences Lecture Series
Testicular Tumours Part 1
Ashray Gunjur Intern, Royal Melbourne Hospital
Testicular cancer: current views Dr. M. Mangala MD (Kin); FRCS (Ireland); MMed (Wits); FCS (SA) Urology 38 th BMA CONGRESS.
Tumors of the testis KVB.
Mr C Dawson Consultant Urologist Edith Cavell Hospital Peterborough
Dr. Kenneth Lim Urology – MSU-COM POH McLaren Medical Center
Testicular Cancer The most common cancer affecting young men in their third or fourth decades of life. Relatively rare: 1-1.5% of all cancer in men Highly.
- In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include:
Neoplasms of the Testis
Campbell’s Chapter 29 Neoplasms of the Testis Brent Zamzow D.O.
Evaluation of nonacute scrotal pathology in adult men
BY DR. KHANSA IQBAL SENIOR REGISTRAR GYNAE UNIT-II.
Computed tomography scan of the abdomen shows a large cystic mass in the abdomen and pelvis without solid tissue or septations (measurement: 43×20×31-cm.
Testicular Cancer Germ Cell Tumors
Question 1 – I may have noticed a lump in my scrotum.
Management of ovarian cysts
Case 1 – I may have noticed a lump in my scrotum
Testicular cancer.
Male Reproductive System Kristine Krafts, M.D.. Male Reproductive System Outline Testis Prostate.
Tumours of the testis 1. Introduction ❏ any solid testicular mass in young patient – must rule out malignancy ❏ slightly more common in right testis (corresponds.
Disorders of Male External Genitalia
Inguinoscrotal mass Case Presentation. Objectives To present the history and physical examination of a patient presenting with inguinoscrotal mass To.
Testicular tumours Urology Case presentation HistoryHistory 2525 C/o hemoptysis, abdominal discomfort;C/o hemoptysis, abdominal discomfort; History.
NON-GERM CELL TUMORS Leydig Cell Tumors Sertoli Cell Tumors Gonadoblastomas.
Dr. Saadeh Jaber OBGYN consultant Epidemiology Second most common gynecological cancer. >35, median 70 It accounts for deaths more than cancer of.
Testicular disease 19th May 2011 Jonathan Chua.
1. Clinical Impression? Differentials?. Thyroid Carcinoma commonly manifests as a painless, palpable, solitary thyroid nodule The patient's age at presentation.
Management of Testicular Tumours Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura Faculty.
Pathology of testis Dr: Salah Ahmed.
Testicular Cancer. Plan Defining the subject and its Epidemiology The Classification and Investigations The Treatment.
Scrotal disorders Dr.Saad Dakhil.
Testicular carcinoma. Epidemilogy 90-95% are germ cell Incidence five times higher among white men Most common solid tumor in males ages often is.
- In the 15- to 34-year-old age group, they are the most common tumors of men. - include: I. Germ cell tumors : 95%; all are malignant. II. Sex cord-stromal.
Helen Forristal Cancer Nurse Co-Ordinator St.Vincent’s University Hospital Case Presentation.
Mark Browning, M.D. ‘77 IUSME
بسم الله الرحمن الرحيم Scrotal Swellings
Testicular Cancer.
Testicular Cancer Dr. Belal M. Hijji, RN. PhD May 30, 2011.
Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.
Testicular tumours Udeh Emeka I Introduction Rare but most curable solid tumour Marked variation in incidence: Scandinavian countries 6.7/
GÖZDE AKAN BERFİN GİZEM USLU
Male Genital System Testis & epididymidis Ductus deferrens
Dr Jane Skeen- for the NZ NCCN Pacific working group
The last lecture. شد الهمة واستعن بالله
Male Reproductive System
TESTICULAR TUMOUR.
Dr . Saadeh Jaber OBGYN consultant 2010
Male genital system.
TESTICULAR TUMORS DR.MOHAMMED ALSHAHWANI.
DENİZ KAVGACI HALİME HELİN YILMAZ
Testicular Cancer.
Presentation transcript:

Testicular tumors

Incidence Testicular tumors are rare. 1 – 2 % of all malignant tumors. Most common malignancy in men in the 15 to 35 year age group. Benign lesions represent a greater percentage of cases in children than in adults.

Age - 3 peaks 2 – 4 yrs 20 – 40 yrs above 60 yrs Testicular cancer is one of the few neoplasms associated with accurate serum markers. Most curable solid neoplasms and serves as a paradigm for the multimodal treatment of malignancies.

Etiology Cryptorchidism Intersex disorder Testicular atrophy Trauma- prompts medical evaluation Chromosomal abnormalities - loss of chromosome 11, 13, 18, abnormal chromosome 12p. Sex hormone fluctuations, estrogen administration during pregnancy

CROSS SECTION OF TESTIS Stroma Seminiferous Tubules (200 to 350 tubules) Interstitial Cells Supporting Spermatogonia Leydig and (Androgen) Sertoli Cell

CLASSIFICATION I. Primary Neoplasms of Testis. A. Germ Cell Tumor. B. Non-Germ Cell Tumor . II. Secondary Neoplasms. III. Paratesticular Tumors.

Germ cell tumors 1. Seminomas - 40% (a) Classic Typical Seminoma (b) Anaplastic Seminoma (c) Spermatocytic Seminoma 2. Embryonal Carcinoma - 20 - 25% 3. Teratoma - 25 - 35% (a) Mature (b) Immature 4. Choriocarcinoma - 1% 5. Yolk Sac Tumour

Sex cord/ gonadal stromal tumors ( 5 to 10% ) 1. Specialized gonadal stromal tumor (a) Leydig cell tumor (b) sertoli cell tumor 2. Gonadoblastoma 3. Miscellaneous Neoplasms (a) Carcinoid tumor (b) Tumors of ovarian epithelial sub types

A. Metastases from any source II. SECONDARY NEOPLASMS OF TESTIS A. Metastases from any source III. PARATESTICULAR NEOPLASMS A. Adenomatoid B. Cystadenoma of Epididymis C. Desmoplastic small round cell tumor D. Mesothelioma E. Melanotic neuroectodermal

Carcinoma insitu {CIS} Pre invasive precusor of all GCT, except spermatocytic seminoma Incidence of CIS in the male population is 0.8%. Testicular CIS develops from fetal gonocytes & is characterized histologically by seminiferous tubules containing only Sertoli cells and malignant germ cells.

Patients at risk of CIS History of testicular carcinoma (5% to 6%), Extra gonadalGCT (40%), Cryptorchidism (3%), Contralateral testis with unilateral testis cancer (5% to 6%), Somatosexual ambiguity (25% to 100%) Atrophic testis 30 % Infertility (0.4% to 1.1%) TESTICULAR BIOPSY gold standard for diagnoses of CIS

Lymphatic drainage The primary drainage of the right testis is within the interaortocaval region. Left testis drainage , the para-aortic region in the compartment bounded by the left ureter, the left renal vein, the aorta, and the origin of the inferior mesenteric artery. Cross over from right to left is possible.

Lymphatic drainage Lymphatics of the epididymis drain into the external iliac chain. Inguinal node metastasis may result from scrotal involvement by the primary tumor, prior inguinal or scrotal surgery, or retrograde lymphatic spread secondary to massive retroperitoneal lymph node deposits. Testicular cancer spreads in a predictable and stepwise fashion, except choriocarcinoma. .

Clinical features Painless Swelling of One testis Dull Ache or Heaviness in Lower Abdomen 10% - Acute Scrotal Pain 10% - Present with Metatstasis - Neck Mass / Cough / Anorexia / Vomiting / Back Ache/ Lower limb swelling 5% - Gynecomastia Rarely - Infertility

Physical Examination Examine contralateral normal testis. Firm to hard fixed area within tunica albugenia is suspicious Seminoma expand within the testis as a painless, rubbery enlargement. Embryonal carcinoma or teratocarcinoma may produce an irregular, rather than discrete mass.

Differential Diagnosis Testicular torsion Epididymitis, or epididymo-orchitis Hydrocele, Hernia, Hematoma, Spermatocele, Syphilitic gumma .

DICTUM FOR ANY SOLID SCROTAL SWELLINGS All patients with a solid, Firm Intratesticular Mass that cannot be Transilluminated should be regarded as Malignant unless otherwise proved.

Scrotal ultrasound Ultrasonography of the scrotum is a rapid, reliable technique to exclude hydrocele or epididymitis. Ultrasonography of the scrotum is basically an extension of the physical examination. Hypoechoic area within the tunica albuginea is markedly suspicious for testicular cancer.

Cystic lesion- epidermoid cyst

Tumor markers TWO MAIN CLASSES Onco-fetal Substances : AFP & HCG Cellular Enzymes : LDH & PLAP AFP - Trophoblastic Cells HCG - Syncytiotrophoblastic Cells ( PLAP- placental alkaline phosphatase, & LDH lactic acid dehydrogenase)

AFP –( Alfafetoprotein) NORMAL VALUE: Below 16 ngm / ml HALF LIFE OF AFP – 5 and 7 days Raised AFP : Pure embryonal carcinoma Teratocarcinoma Yolk sac Tumor Combined tumors, AFP not raised in pure choriocarcinoma , & in pure seminoma

HCG – ( Human Chorionic Gonadotropin) Has  and  polypeptide chain NORMAL VALUE: < 1 ng / ml HALF LIFE of HCG: 24 to 36 hours RAISED  HCG - 100 % - Choriocarcinoma 60% - Embryonal carcinoma 55% - Teratocarcinoma 25% - Yolk Cell Tumour 7% - Seminomas

ROLE OF TUMOUR MARKERS Helps in Diagnosis - 80 to 85% of Testicular Tumours have Positive Markers Most of Non-Seminomas have raised markers Only 10 to 15% Non-Seminomas have normal marker level After Orchidectomy if Markers Elevated means Residual Disease . Elevation of Markers after Lymphadenectomy means a STAGE III Disease

ROLE OF TUMOUR MARKERS Degree of Marker Elevation Appears to be Directly Proportional to Tumor Burden Markers indicate Histology of Tumor: If AFP elevated in Seminoma - Means Tumor has Non-Seminomatous elements Negative Tumor Markers becoming positive on follow up usually indicates - Recurrence of Tumor Markers become Positive earlier than X-Ray studies

Imaging studies Chest X ray CECT abdomen – retroperitoneal nodes PET- No apparent advantage over CT MRI - No apparent advantage over CT

Large left para aortic nodal mass due to GST causing hydronephrosis

Tumor staging Primary Tumor (T)pTX - Primary tumor cannot be assessed (if no radical orchiectomy has been performed, TX is used) pT0 - No evidence of primary tumor (e.g., histologic scar in testis) pTis - Intratubular germ cell neoplasia (carcinoma in situ) pT1 - Tumor limited to the testis and epididymis and no vascular/lymphatic invasion pT2 - Tumor limited to the testis and epididymis with vascular/lymphatic invasion or tumor extending through the tunica albuginea with involvement of tunica vaginalis pT3 - Tumor invades the spermatic cord with or without vascular/lymphatic invasion pT4 - Tumor invades the scrotum with or without vascular/lymphatic invasion

Regional Lymph Nodes Clinical NX - Regional lymph nodes cannot be assessed N0 - No regional lymph node metastasis N1 - Lymph node mass 2 cm or less in greatest dimension or multiple lymph node masses, none more than 2 cm in greatest dimension N2 - Lymph node mass, more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph node masses, any one mass greater than 2 cm but not more than 5 cm in greatest dimension N3 - Lymph node mass more than 5 cm in greatest dimension

Pathologic node staging pN0 - No evidence of tumor in lymph nodes pN1 - Lymph node mass, 2 cm or less in greatest dimension and ≤6 nodes positive, none >2 cm in greatest dimension pN2 - Lymph node mass, more than 2 cm but not more than 5 cm in greatest dimension; more than 5 nodes positive, none >5 cm; evidence of extranodal extension of tumor pN3 - Lymph node mass more than 5 cm in greatest dimension.

Distant metastasis M0 - No evidence of distant metastases M1 - Nonregional nodal or pulmonary metastases M2 - Nonpulmonary visceral masses

Serum tumor markers LDH HCG Miu/ml AFP Ng/ml S0 _< N <N S1 <1.5 x N < 5000 < 1000 S2 1.5-10x N 5000 to 50000 1000 to 10000 S3 >10x N > 50000 >10000

PRINCIPLES OF TREATMENT Treatment should be aimed at one stage above the clinical stage Seminomas - Radio-Sensitive. Treat with Radiotherapy. Non-Seminomas are Radio-Resistant and best treated by Surgery Advanced Disease or Metastasis - Responds well to Chemotherapy

PRINCIPLES OF TREATMENT Radical INGUINAL ORCHIDECTOMY is Standard first line of therapy Lymphatic spread initially goes to RETRO-PERITONEAL NODES Early hematogenous spread RARE Bulky Retroperitoneal Tumours or Metastatic Tumors Initially “DOWN-STAGED” with CHEMOTHERAPY

PRINCIPLES OF TREATMENT Transscrotal biopsy is to be condemned. The inguinal approach permits early control of the vascular and lymphatic supply as well as en-bloc removal of the testis with all its tunicae. Frozen section in case of dilemma.

Chemotherapy Toxicity BEP - Bleomycin Pulmonary fibrosis Etoposide (VP-16) Myelosuppression Alopecia Renal insufficiency (mild) Secondary leukemia Cis-platin Renal insufficiency Nausea, vomiting Neuropathy

Lymph Nodes Dissection For Right & Left Sided Testicular Tumours

CONCLUSION Improved Overall Survival of Testicular Tumour due to Better Understanding of the Disease, Tumour Markers and Cis-platinum based Chemotherapy. Current Emphasis is on Diminishing overall Morbidity of Various Treatment Modalities .

THANK YOU